Imatinib mesylate in the treatment of chronic myelogenous leukemia

被引：16

作者：

Borthakur, G

Cortes, JE

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas, Hlth Sci Ctr, Div Hematol, Houston, TX USA

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2004年 / 79卷 / 05期

关键词：

chronic myeloid leukemia; imatinib;

D O I：

10.1532/IJH97.04054

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Imatimb mesylate binds to the inactive conformation of BCR-ABL tyrosine kinase, suppressing the Philadelphia chromosome-positive clone in chronic myelogenous leukemia (CML). Clinical studies of imatinib have yielded impressive results in the treatment of all phases of CML. With the higher rates of complete cytogenetic response with imatinib, molecular monitoring of disease has become mandatory in assessing response and determining prognosis. The practical aspects of the treatment of CML with imatinib are discussed. The emergence of imatinib resistance, albeit in a small percentage of patients, has prompted an evaluation of innovative treatment strategies. (C) 2004 The Japanese Society of Hematology.

引用

页码：411 / 419

页数：9

共 69 条

[1]

AULT P, 2003, BLOOD, V102

[2]

AULT P, 2003, P AN M AM SOC CLIN, V22, P613

[3]

BACCARANI M, 2002, BLOOD, V100

[4] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[5] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[6]

BRUKER BJ, 2001, BLOOD, V98, pA839

[7]

Buchdunger E, 1996, CANCER RES, V56, P100

[8]

Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139

[9]

Cervantes F, 2003, HAEMATOLOGICA, V88, P1117

[10] Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia [J].

Cortes, J ;

Talpaz, M ;

O'Brien, S ;

Giles, F ;

Rios, MB ;

Shan, JQ ;

Faderl, S ;

Garcia-Manero, G ;

Ferrajoli, A ;

Wierda, W ;

Kantarjian, H .

CANCER, 2003, 98 (06) :1105-1113

← 1 2 3 4 5 6 7 →